{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:34:19Z","timestamp":1790476459365,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019337","name":"Miami Clinical and Translational Science Institute, University of Miami","doi-asserted-by":"publisher","award":["UL1TR002736"],"award-info":[{"award-number":["UL1TR002736"]}],"id":[{"id":"10.13039\/100019337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.amjcard.2023.07.140","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T11:07:30Z","timestamp":1691752050000},"page":"360-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Safety and Efficacy of Traditional Heart Failure Therapies in Patients With Cardiac Amyloidosis and Heart Failure"],"prefix":"10.1016","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1724-4231","authenticated-orcid":false,"given":"Crystal Lihong","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan A.","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moises","family":"Vasquez Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Rivera Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Trujillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Thakkar Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2023.07.140_bib0001","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13506129.2020.1835263","article-title":"Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"27","author":"Benson","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0002","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north Scandinavian enalapril survival study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0003","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0004","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0005","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0006","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0007","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0008","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s00508-020-01781-z","article-title":"Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement","volume":"132","author":"Bonderman","year":"2020","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0009","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0010","first-page":"e7","article-title":"Cardiac amyloidosis: evolving diagnosis and management: A scientific statement from the American Heart Association [published correction appears in Circulation 2021;144:e10] [published correction appears in Circulation 2021;144:e11]","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0011","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ejhf.1351","article-title":"Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges","volume":"21","author":"Marti","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0012","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022859","article-title":"Lack of association between neurohormonal blockade and survival in transthyretin cardiac amyloidosis","volume":"10","author":"Cheng","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0013","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0014","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0015","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","article-title":"Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service Medicare beneficiaries in the United States","volume":"12","author":"Gilstrap","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0016","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.hlc.2022.08.002","article-title":"Prevalence and risk factors of cardiac amyloidosis in heart failure: A systematic review and meta-analysis","volume":"31","author":"See","year":"2022","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0017","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0018","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jaccao.2021.06.006","article-title":"ATTR amyloidosis: current and emerging management strategies: JACC: CardioOncology state-of-the-art review","volume":"3","author":"Griffin","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0019","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejim.2020.05.015","article-title":"Safety and tolerability of neurohormonal antagonism in cardiac amyloidosis","volume":"80","author":"Aimo","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0021","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1002\/ehf2.13411","article-title":"Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey","volume":"8","author":"Tini","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0022","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1093\/eurheartj\/ehac543","article-title":"Restrictive cardiomyopathy: definition and diagnosis","volume":"43","author":"Rapezzi","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0023","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1080\/13506129.2021.1966624","article-title":"Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure","volume":"28","author":"Vergaro","year":"2021","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0024","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0025","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0026","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0027","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","article-title":"Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis","volume":"26","author":"Lohrmann","year":"2020","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0028","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0029","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.amjcard.2023.07.140_bib0030","unstructured":"Apollo B. A study to evaluate patisiran in participants with transthyretin amyloidosis with cardiomyopathy (ATTR amyloidosis with cardiomyopathy). NIH, U.S. National Library of Medicine. Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03997383. Accessed on July 12, 2023."},{"key":"10.1016\/j.amjcard.2023.07.140_bib0031","unstructured":"CARDIO-TTRansform: A study to evaluate the efficacy and safety of eplontersen (formerly known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in participants with transthyretin-mediated amyloid cardiomyopathy (ATTR CM). NIH, U.S. National Library of Medicine. Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04136171. Accessed on July 12, 2023."},{"key":"10.1016\/j.amjcard.2023.07.140_bib0032","unstructured":"Helios B. A study to evaluate vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. NIH, U.S. National Library of Medicine. Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04153149. Accessed on July 12, 2023."},{"key":"10.1016\/j.amjcard.2023.07.140_bib0033","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923006914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923006914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:50:13Z","timestamp":1757573413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914923006914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":33,"alternative-id":["S0002914923006914"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.07.140","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Traditional Heart Failure Therapies in Patients With Cardiac Amyloidosis and Heart Failure","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.07.140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}